Abpro Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Private

  • Employees
  • 40

Employees

  • Latest Deal Type
  • PIPE

  • Latest Deal Amount
  • $5M

  • Investors
  • 1

Abpro General Information

Description

Operator of a biotechnology company intended to treat and cure diseases in patients. The company uses synthetic biology and immunology to generate medication against novel and challenging targets, enabling biotechnology and pharmaceutical companies to develop many therapeutic antibodies against traditionally difficult targets, helping medical professionals create antibody therapies to improve the lives of patients facing severe and life-threatening diseases.

Contact Information

Website
www.abpro.co
Formerly Known As
IE LAB
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • 100 Summit Drive
  • Burlington, MA 01803
  • United States
+1 (800)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 100 Summit Drive
  • Burlington, MA 01803
  • United States
+1 (800)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Abpro Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. PIPE 13-Nov-2024 $5M Completed Generating Revenue
9. Reverse Merger 13-Nov-2024 Completed Clinical Trials - Phase 2
8. Later Stage VC (Series F) 06-Apr-2022 Completed Clinical Trials - Phase 2
7. Debt - PPP 14-Apr-2020 Completed Clinical Trials - Phase 2
6. Later Stage VC (Series E) 27-Jan-2020 Completed Clinical Trials - Phase 2
5. IPO 11-May-2018 Cancelled Clinical Trials - Phase 2
4. Later Stage VC (Series D) 07-Apr-2017 Completed Clinical Trials - Phase 2
3. Later Stage VC (Series C) 06-Apr-2016 Completed Clinical Trials - Phase 2
2. Later Stage VC (Series B) 11-Aug-2015 $5.2M $7M Completed Clinical Trials - Phase 2
1. Early Stage VC (Series A) 20-Sep-2007 $1.8M $1.8M Completed Pre-Clinical Trials
To view Abpro’s complete valuation and funding history, request access »

Abpro Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series F
Series E
Series D
Series C
Series B 626,636 $0.001000 $2.87 $2.87 1x $2.87 1.78%
Series A 19,254 $0.001000 $93.23 $93.23 1x $0.93 5.48%
To view Abpro’s complete cap table history, request access »

Abpro Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology company intended to treat and cure diseases in patients. The company uses synthetic biology
Drug Discovery
Burlington, MA
40 As of 2025

New Haven, CT
 

Germantown, MD
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Abpro Competitors (14)

One of Abpro’s 14 competitors is Invivyd, a Formerly VC-backed company based in New Haven, CT.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Invivyd Formerly VC-backed New Haven, CT
Precigen Formerly VC-backed Germantown, MD
F-Star Therapeutics Formerly VC-backed Cambridge, United Kingdom
Genmab Formerly VC-backed Valby, Denmark
Sutro Biopharma Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 14 competitors. Get the full list »

Abpro Patents

  • 28

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 15

    Pending

  • Expiring in next 12 mo

Abpro Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023150307-A2 Compositions and methods against a virus Inactive 03-Feb-2022
WO-2023150307-A3 Compositions and methods against a virus Inactive 03-Feb-2022
AU-2022324015-A1 Anti-her2 antibodies and uses thereof Pending 04-Aug-2021
CA-3228259-A1 Anti-her2 antibodies and uses thereof Pending 04-Aug-2021
EP-4380638-A2 Anti-her2 antibodies and uses thereof Pending 04-Aug-2021 C07K16/32
To view Abpro’s complete patent history, request access »

Abpro Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Abpro Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Atlantic Coastal Acquisition II Special Purpose Acquisition Company (SPAC) Minority
To view Abpro’s complete investors history, request access »

Abpro Acquisitions (1)

Abpro’s most recent deal was a Merger/Acquisition with Atlantic Coastal Acquisition II. The deal was made on 13-Nov-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Atlantic Coastal Acquisition II 13-Nov-2024 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
To view Abpro’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Abpro FAQs

  • When was Abpro founded?

    Abpro was founded in 2004.

  • Where is Abpro headquartered?

    Abpro is headquartered in Burlington, MA.

  • What is the size of Abpro?

    Abpro has 40 total employees.

  • What industry is Abpro in?

    Abpro’s primary industry is Drug Discovery.

  • Is Abpro a private or public company?

    Abpro is a Private company.

  • What is Abpro’s current revenue?

    The current revenue for Abpro is .

  • How much funding has Abpro raised over time?

    Abpro has raised $54.4M.

  • Who are Abpro’s investors?

    Atlantic Coastal Acquisition II has invested in Abpro.

  • Who are Abpro’s competitors?

    Invivyd, Precigen, F-Star Therapeutics, Genmab, and Sutro Biopharma are some of the 14 competitors of Abpro.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process